Eribulin

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1117 publications

Across borders and histologies: Rethinking endpoints for vascular sarcoma trials.

Across borders and histologies: Rethinking endpoints for vascular sarcoma trials.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 25, 2026

Effects of Eribulin on Epithelial-Mesenchymal Plasticity in Patient-Derived Breast Cancer Cultures and Excised Tissues.

Effects of Eribulin on Epithelial-Mesenchymal Plasticity in Patient-Derived Breast Cancer Cultures and Excised Tissues.

Journal: Cancers

Published: January 10, 2026

Does coordinated targeting of metabolism and autophagy, modulated by microtubule dynamics, influence therapeutic vulnerability to eribulin in glioblastoma?

Does coordinated targeting of metabolism and autophagy, modulated by microtubule dynamics, influence therapeutic vulnerability to eribulin in glioblastoma?

Journal: Translational cancer research

Published: January 07, 2026

The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives.

The Role of Natural Product Chemistry in Drug Discovery: Two Decades of Progress and Perspectives.

Journal: Journal of natural products

Published: December 26, 2025

Modern synthetic pathways towards eribulin and its subunits.

Modern synthetic pathways towards eribulin and its subunits.

Journal: Beilstein journal of organic chemistry

Published: December 17, 2025

Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay.

Epigenetic Activity of Cancer Therapy Drugs Revealed by HeLa TI Cell-Based Assay.

Journal: Epigenomes

Published: November 20, 2025

CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.

CSF1R Inhibition with Chemotherapy Relieves Systemic Immune Suppression in Patients with Metastatic Triple-Negative Breast Cancer and Boosts anti-PD-1 Efficacy in Transgenic Mammary Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 06, 2025

A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy.

A Japanese Multicenter Database Study of Retroperitoneal Sarcoma: Outcomes of Patients Receiving Eribulin Therapy.

Journal: Asia-Pacific journal of clinical oncology

Published: October 29, 2025

Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study.

Identifying immune-related predictive factors for post-eribulin therapy in patients with HER2-negative advanced breast cancer- a multicenter retrospective study.

Journal: International journal of clinical oncology

Published: October 27, 2025

Clinical outcome of 50 patients treated with eribulin for soft tissue sarcoma: a single-institute retrospective study.

Clinical outcome of 50 patients treated with eribulin for soft tissue sarcoma: a single-institute retrospective study.

Journal: Japanese journal of clinical oncology

Published: October 24, 2025

Marine-Derived Anticancer Compounds and their Clinical Status.

Marine-Derived Anticancer Compounds and their Clinical Status.

Journal: Anti-cancer agents in medicinal chemistry

Published: October 17, 2025

Eribulin and sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review.

Eribulin and sintilimab combined with radiotherapy in a heavily pretreated patient with advanced retroperitoneal myxoid pleomorphic liposarcoma: a case report and literature review.

Journal: Frontiers in oncology

Published: October 06, 2025

Showing 1-12 of 1,117

Last Updated: 04/28/2026